Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
11 avr. 2024 08h55 HE
|
Oculis Holding AG
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved...
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
10 avr. 2024 06h30 HE
|
Oculis Holding AG
Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team...
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
08 avr. 2024 06h30 HE
|
Oculis Holding AG
OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2...
Oculis to Participate at Upcoming April Investor Conferences
04 avr. 2024 06h30 HE
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
18 mars 2024 06h30 HE
|
Oculis Holding AG
A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for...
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
28 févr. 2024 06h30 HE
|
Oculis Holding AG
Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3...
Oculis to Present at Upcoming February Investor Conferences
29 janv. 2024 06h30 HE
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22 janv. 2024 06h30 HE
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and...
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
20 déc. 2023 06h30 HE
|
Oculis Holding AG
Initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop, follows the recently reported positive OPTIMIZE-1 trial results OPTIMIZE-2 topline readout expected before end of...
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
18 déc. 2023 06h30 HE
|
Oculis Holding AG
DIAMOND-1 Phase 3 trial, assessing the efficacy and safety of OCS-01 eye drops following 52 weeks of treatment in Diabetic Macular Edema (DME) patients, was initiated as plannedStage 1 results showed...